Rocket Pharmaceuticals Inc（RCKT）财务数据RCKTRocket Pharmaceuticals Inc

Evaluating the bottom line, Rocket Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -4.77%, provide a clear picture of how effectively RCKT converts its operational activities into shareholder value.

In the context of the broader market, RCKT competes directly with industry leaders such as BNTC and FENC. With a market capitalization of $423.73M, it holds a significant position in the sector. When comparing efficiency, RCKT's gross margin of N/A stands against BNTC's N/A and FENC's 95.97%. Such benchmarking helps identify whether Rocket Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Rocket Pharmaceuticals has shown a recent turnaround in financial performance with a reported net income of $123.2 million in Q2 2026, following several quarters of losses, indicating potential for future profitability.